2000
Hsl1p, a Swe1p Inhibitor, Is Degraded via the Anaphase-Promoting Complex
Burton J, Solomon M. Hsl1p, a Swe1p Inhibitor, Is Degraded via the Anaphase-Promoting Complex. Molecular And Cellular Biology 2000, 20: 4614-4625. PMID: 10848588, PMCID: PMC85864, DOI: 10.1128/mcb.20.13.4614-4625.2000.Peer-Reviewed Original ResearchMeSH KeywordsAmino Acid MotifsAnaphase-Promoting Complex-CyclosomeApc8 Subunit, Anaphase-Promoting Complex-CyclosomeBase SequenceCdc20 ProteinsCdh1 ProteinsCell CycleCell Cycle ProteinsCyclin-Dependent KinasesFungal ProteinsGenes, DominantLigasesMolecular Sequence DataMutationPrecipitin TestsProtein KinasesProtein Serine-Threonine KinasesProtein-Tyrosine KinasesSaccharomyces cerevisiae ProteinsTwo-Hybrid System TechniquesUbiquitin-Protein Ligase ComplexesUbiquitin-Protein LigasesYeastsConceptsAnaphase-promoting complexDestruction box motifCell cycle eventsProtein kinaseBox motifCycle eventsCyclin-dependent kinase Cdc28pCritical cell cycle regulatorsAPC-dependent mannerCell cycle regulatorsSwe1p degradationMorphogenesis checkpointAPC substratesHsl1pLate mitosisProper progressionProtein substratesUbiquitin ligaseCoimmunoprecipitation studiesSequence homologyCycle regulatorsUbiquitinationSubsequent degradationKinaseCdc20p
1998
Human and Yeast Cdk-activating Kinases (CAKs) Display Distinct Substrate Specificities
Kaldis P, Russo A, Chou H, Pavletich N, Solomon M. Human and Yeast Cdk-activating Kinases (CAKs) Display Distinct Substrate Specificities. Molecular Biology Of The Cell 1998, 9: 2545-2560. PMID: 9725911, PMCID: PMC25525, DOI: 10.1091/mbc.9.9.2545.Peer-Reviewed Original ResearchConceptsTranscription factor IIHC-terminal domainSubstrate specificityCDK/cyclin complexesCTD kinase activityRNA polymerase IIDistinct substrate specificitiesDifferent substrate specificitiesCyclin-dependent kinasesCell cycle progressionHuman CAKYeast CdkEnzyme-substrate recognitionPolymerase IILarge subunitTranscriptional componentsCak1pCDK activationCyclin complexesKey residuesKinase activitySingle polypeptideCycle progressionCDK inhibitorsCDK